SAMSUNG PHARM. Co., LTD. (001360.KS)
KRW 1603.0
(0.25%)
KRW 1603.0
(0.25%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 15.89 Billion KRW | 3.72% |
| 2022 | 15.32 Billion KRW | -15.73% |
| 2021 | 18.18 Billion KRW | -67.99% |
| 2020 | 56.81 Billion KRW | 121.03% |
| 2019 | 25.7 Billion KRW | -11.32% |
| 2018 | 28.98 Billion KRW | -51.95% |
| 2017 | 60.32 Billion KRW | 7.9% |
| 2016 | 55.9 Billion KRW | -33.43% |
| 2015 | 83.98 Billion KRW | 146.17% |
| 2014 | 34.11 Billion KRW | -44.47% |
| 2013 | 61.43 Billion KRW | -10.05% |
| 2012 | 68.3 Billion KRW | 26.3% |
| 2011 | 54.08 Billion KRW | 22.6% |
| 2010 | 44.11 Billion KRW | 19.14% |
| 2009 | 37.02 Billion KRW | 20.79% |
| 2008 | 30.65 Billion KRW | -1.61% |
| 2007 | 31.15 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 18.99 Billion KRW | 19.52% |
| 2024 Q2 | 17.28 Billion KRW | -8.99% |
| 2023 Q1 | 17.37 Billion KRW | 13.36% |
| 2023 Q4 | 15.89 Billion KRW | 18.06% |
| 2023 Q3 | 13.46 Billion KRW | -16.5% |
| 2023 FY | 15.89 Billion KRW | 3.72% |
| 2023 Q2 | 16.12 Billion KRW | -7.18% |
| 2022 Q3 | 15.47 Billion KRW | 2.65% |
| 2022 FY | 15.32 Billion KRW | -15.73% |
| 2022 Q4 | 15.32 Billion KRW | -0.99% |
| 2022 Q1 | 12.04 Billion KRW | -33.79% |
| 2022 Q2 | 15.07 Billion KRW | 25.23% |
| 2021 Q4 | 18.18 Billion KRW | 23.84% |
| 2021 Q3 | 14.68 Billion KRW | -4.81% |
| 2021 Q2 | 15.42 Billion KRW | -0.81% |
| 2021 Q1 | 15.55 Billion KRW | -72.62% |
| 2021 FY | 18.18 Billion KRW | -67.99% |
| 2020 Q3 | 47.21 Billion KRW | -4.46% |
| 2020 Q1 | 45.1 Billion KRW | 0.0% |
| 2020 Q2 | 49.41 Billion KRW | 9.55% |
| 2020 Q4 | 56.81 Billion KRW | 20.33% |
| 2020 FY | 56.81 Billion KRW | 121.03% |
| 2019 FY | 25.7 Billion KRW | -11.32% |
| 2019 Q1 | 28.01 Billion KRW | -3.35% |
| 2019 Q2 | 24.88 Billion KRW | -11.15% |
| 2019 Q3 | 24.64 Billion KRW | -0.99% |
| 2018 Q1 | 55.99 Billion KRW | -7.18% |
| 2018 Q4 | 28.98 Billion KRW | -12.27% |
| 2018 Q2 | 33.45 Billion KRW | -40.26% |
| 2018 FY | 28.98 Billion KRW | -51.95% |
| 2018 Q3 | 33.03 Billion KRW | -1.24% |
| 2017 FY | 60.32 Billion KRW | 7.9% |
| 2017 Q4 | 60.32 Billion KRW | -6.75% |
| 2017 Q3 | 64.68 Billion KRW | 0.67% |
| 2017 Q2 | 64.25 Billion KRW | 13.97% |
| 2017 Q1 | 56.37 Billion KRW | 0.84% |
| 2016 FY | 55.9 Billion KRW | -33.43% |
| 2016 Q4 | 55.9 Billion KRW | -18.59% |
| 2016 Q3 | 68.67 Billion KRW | 1.42% |
| 2016 Q2 | 67.71 Billion KRW | -21.0% |
| 2016 Q1 | 85.71 Billion KRW | 2.07% |
| 2015 Q2 | 56.34 Billion KRW | 0.0% |
| 2015 Q3 | 72.83 Billion KRW | 29.28% |
| 2015 Q4 | 83.98 Billion KRW | 15.3% |
| 2015 FY | 83.98 Billion KRW | 146.17% |
| 2014 FY | 34.11 Billion KRW | -44.47% |
| 2014 Q4 | 34.11 Billion KRW | 0.0% |
| 2014 Q1 | 58.5 Billion KRW | -4.77% |
| 2013 FY | 61.43 Billion KRW | -10.05% |
| 2013 Q4 | 61.43 Billion KRW | 1.31% |
| 2013 Q3 | 60.64 Billion KRW | -6.03% |
| 2013 Q2 | 64.53 Billion KRW | 7.74% |
| 2013 Q1 | 59.89 Billion KRW | -12.31% |
| 2012 Q1 | 60.05 Billion KRW | 11.04% |
| 2012 Q2 | 56.73 Billion KRW | -5.52% |
| 2012 Q3 | 59.41 Billion KRW | 4.71% |
| 2012 Q4 | 68.3 Billion KRW | 14.96% |
| 2012 FY | 68.3 Billion KRW | 26.3% |
| 2011 Q4 | 54.08 Billion KRW | -0.34% |
| 2011 Q2 | 53.6 Billion KRW | 6.28% |
| 2011 Q1 | 50.43 Billion KRW | 14.35% |
| 2011 Q3 | 54.26 Billion KRW | 1.23% |
| 2011 FY | 54.08 Billion KRW | 22.6% |
| 2010 Q2 | 41.07 Billion KRW | 9.26% |
| 2010 Q3 | 41.92 Billion KRW | 2.07% |
| 2010 Q4 | 44.11 Billion KRW | 5.21% |
| 2010 Q1 | 37.59 Billion KRW | 1.55% |
| 2010 FY | 44.11 Billion KRW | 19.14% |
| 2009 Q3 | 36.88 Billion KRW | 13.97% |
| 2009 Q1 | 32.24 Billion KRW | 5.2% |
| 2009 Q4 | 37.02 Billion KRW | 0.39% |
| 2009 Q2 | 32.36 Billion KRW | 0.37% |
| 2009 FY | 37.02 Billion KRW | 20.79% |
| 2008 Q2 | 29.97 Billion KRW | 3.91% |
| 2008 Q3 | 29.33 Billion KRW | -2.14% |
| 2008 Q4 | 30.65 Billion KRW | 4.48% |
| 2008 FY | 30.65 Billion KRW | -1.61% |
| 2008 Q1 | 28.85 Billion KRW | -7.39% |
| 2007 Q3 | 30.34 Billion KRW | 4.92% |
| 2007 FY | 31.15 Billion KRW | 0.0% |
| 2007 Q4 | 31.15 Billion KRW | 2.68% |
| 2007 Q1 | 27.77 Billion KRW | 0.0% |
| 2007 Q2 | 28.91 Billion KRW | 4.12% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | 79.585% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 98.291% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 97.752% |
| HANDOK Inc. | 449.7 Billion KRW | 96.466% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | 81.447% |
| Yuhan Corporation | 712.33 Billion KRW | 97.769% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | 97.485% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 98.134% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | 70.307% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 92.28% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | 78.856% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | 89.246% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | 77.423% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | 79.585% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | 56.377% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | 93.671% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | 92.798% |
| JW Holdings Corporation | 827.51 Billion KRW | 98.079% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | 96.363% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 97.291% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 95.813% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | 79.957% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | 77.283% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | 93.455% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | 95.188% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | 79.585% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | 96.756% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 98.148% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 95.813% |
| Yuhan Corporation | 712.33 Billion KRW | 97.769% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | 96.673% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | 88.396% |
| Suheung Co., Ltd. | 516.66 Billion KRW | 96.924% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 95.813% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | 89.715% |
| Korea United Pharm Inc. | 89.96 Billion KRW | 82.333% |
| CKD Bio Corp. | 170.76 Billion KRW | 90.692% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | 93.479% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | 89.918% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | 63.053% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | 79.957% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 97.487% |
| Boryung Corporation | 373.1 Billion KRW | 95.74% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | 92.366% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 92.28% |
| JW Lifescience Corporation | 96.44 Billion KRW | 83.519% |